Laboratoire d'Enzymologie et Biochimie Structurales, CNRS, Gif-sur-Yvette, France.
PLoS One. 2013 Apr 16;8(4):e60895. doi: 10.1371/journal.pone.0060895. Print 2013.
The molecular chaperone CCT/TRiC plays a central role in maintaining cellular proteostasis as it mediates the folding of the major cytoskeletal proteins tubulins and actins. CCT/TRiC is also involved in the oncoprotein cyclin E, the Von Hippel-Lindau tumour suppressor protein, cyclin B and p21(ras) folding which strongly suggests that it is involved in cell proliferation and tumor genesis. To assess the involvement of CCT/TRiC in tumor genesis, we quantified its expression levels and activity in 18 cancer, one non-cancer human cell lines and a non-cancer human liver. We show that the expression levels of CCT/TRiC in cancer cell lines are higher than that in normal cells. However, CCT/TRiC activity does not always correlate with its expression levels. We therefore documented the expression levels of CCT/TRiC modulators and partners PhLP3, Hop/P60, prefoldin and Hsc/Hsp70. Our analysis reveals a functional interplay between molecular chaperones that might account for a precise modulation of CCT/TRiC activity in cell proliferation through changes in the cellular levels of prefoldin and/or Hsc/p70 and CCT/TRiC client protein availability. Our observation and approaches bring novel insights in the role of CCT/TRiC-mediated protein folding machinery in cancer cell development.
分子伴侣 CCT/TRiC 在维持细胞蛋白稳态中起着核心作用,因为它介导主要细胞骨架蛋白微管蛋白和肌动蛋白的折叠。CCT/TRiC 还参与癌蛋白细胞周期蛋白 E、Von Hippel-Lindau 肿瘤抑制蛋白、细胞周期蛋白 B 和 p21(ras)的折叠,这强烈表明它参与细胞增殖和肿瘤发生。为了评估 CCT/TRiC 在肿瘤发生中的作用,我们在 18 种癌症、一种非癌症人类细胞系和一种非癌症人类肝脏中定量检测了其表达水平和活性。我们发现癌症细胞系中 CCT/TRiC 的表达水平高于正常细胞。然而,CCT/TRiC 的活性并不总是与其表达水平相关。因此,我们记录了 CCT/TRiC 调节剂和伴侣 PhLP3、Hop/P60、前折叠酶和 Hsc/Hsp70 的表达水平。我们的分析揭示了分子伴侣之间的功能相互作用,这可能通过改变细胞内前折叠酶和/或 Hsc/p70 和 CCT/TRiC 客户蛋白的可用性来精确调节 CCT/TRiC 活性,从而在细胞增殖中发挥作用。我们的观察和方法为 CCT/TRiC 介导的蛋白质折叠机制在癌细胞发育中的作用提供了新的见解。